Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Insilico Announces Six-Drug, $1.2 Billion AI Drug Discovery Deal with Sanofi

publication date: Nov 8, 2022

Insilico Medicine, a Hong Kong-New York City AI drug discovery company, signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each of the six targets. It will also be eligible for milestone and royalty payments. Insilico will apply its end-to-end Pharma.AI platform to the Sanofi targets, including interdisciplinary drug discovery scientists who will advance lead therapeutic compounds up to candidate development stage. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here